Yahoo
Stockholm - Delayed Quote SEK

Ascelia Pharma AB (publ) (ACE.ST)

0.5900 +0.0400 (+7.27%)
At close: 5:29:58 PM GMT+2
ACE.ST Q2 2026 earnings call
August 21, 2026 at 10 AM GMT+2
Chart Range Bar
Loading chart for ACE.ST
  • Previous Close 0.5500
  • Open 0.5980
  • Bid 0.5610 x --
  • Ask 0.5750 x --
  • Day's Range 0.5530 - 0.5980
  • 52 Week Range 0.4550 - 5.1300
  • Volume 746,957
  • Avg. Volume 2,247,559
  • Market Cap (intraday) 78.786M
  • Beta (5Y Monthly) 0.83
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5700
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.40

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.

www.ascelia.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/20/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

ACE.ST
81.65%
OMX Stockholm 30 Index (^OMX)
13.02%

1-Year Return

ACE.ST
87.12%
OMX Stockholm 30 Index (^OMX)
22.71%

3-Year Return

ACE.ST
81.96%
OMX Stockholm 30 Index (^OMX)
51.86%

5-Year Return

ACE.ST
98.14%
OMX Stockholm 30 Index (^OMX)
38.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY25
Revenue --
Earnings -15.67M

Q4

FY24

Q1

FY25

Q2

FY25

Q3

FY25

-20M
-10M
0

Analyst Insights

View More

Analyst Price Targets

1.00
2.40 Average
0.5900 Current
3.70 High

Statistics

View More

Valuation Measures

Annual
As of 8/18/2026
  • Market Cap

    77.05M

  • Enterprise Value

    43.85M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.93

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -40.35%

  • Return on Equity (ttm)

    -100.75%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -70.9M

  • Diluted EPS (ttm)

    -0.5700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    33.89M

  • Total Debt/Equity (mrq)

    0.83%

  • Levered Free Cash Flow (ttm)

    -62.8M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: